Less bleeding seen with rivaroxaban in large lung clot study

03/27/2012 | Reuters

The anticoagulant rivaroxaban is safer than and works as well as standard dual therapy for blood clots of the lung, according to a 4,833-patient study presented at a cardiology meeting. A lower percentage of patients taking rivaroxaban experienced major and minor bleeding compared with those who took the combination therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC